STEP 3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Harriet Oduya
Page 8 of 10 of this archive, newest first.
Archive — page 8
192 piecesLEADER misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Medutest result on a Xi'an semaglutide lot lands 3.3 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
LEADER extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Janoshik result on a Wuxi survodutide lot lands 2.9 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
Why a 0.036-dalton difference is the hardest number in peptide identity
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
SURMOUNT-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a TFC mazdutide lot at 98.4%, against 95.9% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The lead-in, the randomisation, and the year that followed
The regain trajectories, arm by arm, with the estimands named.
The dose that got you here and the dose that keeps you here
The commonest real-world strategy in this drug class is the least studied one.
SURMOUNT-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Two scans, six weeks apart, and the arithmetic of believing the difference
A body-composition report gives four decimal places and no confidence interval. That is the whole difficulty in one sentence.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Electrospray, MALDI, and the choice that shapes every spectrum after it
A brief and unromantic tour of the interface between a liquid sample and a vacuum.
We split six vials four ways and posted them
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
The glycated haemoglobin assay, and the eight conditions that break it
The alternatives with shorter windows, what they measure, and why they are rarely ordered.
Grams per kilogram of what? The denominator problem in protein guidance
Where the familiar figures come from, what populations they were measured in, and how far the extrapolation reaches.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The lowest effective dose is a real concept with almost no data behind it
The commonest real-world strategy in this drug class is the least studied one.